Veru Inc. has enrolled the first patient in its Phase 2b PLATEAU clinical trial evaluating the oral selective androgen receptor modulator enobosarm in combination with semaglutide for obesity treatment in older adults. The study will assess whether enobosarm can preserve lean muscle mass, maintain physical function, and improve body composition while patients receive semaglutide therapy, a glucagon-like peptide-1 receptor agonist widely used for weight reduction.

The milestone places the United States-based biopharmaceutical developer into an increasingly important debate in metabolic medicine. While GLP-1 receptor agonists such as semaglutide have transformed obesity treatment by producing unprecedented pharmacological weight loss, researchers increasingly recognize that significant reductions in body weight can also involve losses of lean tissue. This concern is prompting interest in combination therapies designed to preserve muscle mass while maintaining the metabolic benefits of incretin-based drugs.

Why the obesity drug industry is beginning to examine body composition rather than weight loss alone

The global obesity drug market expanded rapidly following the clinical success of GLP-1 receptor agonists. These therapies demonstrated weight reductions far exceeding those achieved by earlier pharmacological treatments and helped redefine expectations for medical obesity management. Pharmaceutical companies subsequently accelerated development programs targeting metabolic diseases associated with obesity.

However, researchers evaluating the physiological effects of incretin therapies have increasingly focused on how weight loss occurs rather than simply how much weight is lost. Imaging studies suggest that pharmacological weight reduction frequently includes measurable declines in lean tissue such as skeletal muscle. Although some lean mass reduction is expected during weight loss, the magnitude of weight reduction produced by modern incretin drugs has intensified attention on the issue.

Industry observers note that lean mass preservation becomes particularly important in older patients with obesity. Aging is already associated with sarcopenia, a gradual decline in muscle mass and strength that can impair mobility and increase vulnerability to frailty. If rapid pharmacological weight loss accelerates that decline, physicians could face a therapeutic paradox in which metabolic improvements occur alongside reduced functional resilience.

These concerns have begun influencing research priorities in obesity medicine. Investigators increasingly discuss the concept of higher quality weight loss, emphasizing reductions in fat mass while maintaining muscle tissue and physical capability. The PLATEAU trial reflects this evolving focus by examining whether pharmacological intervention can modify the composition of weight reduction rather than simply increasing its magnitude.

How Veru Inc.’s enobosarm program attempts to address muscle loss during GLP-1 therapy

Enobosarm belongs to a class of experimental compounds known as selective androgen receptor modulators. These molecules stimulate androgen receptors in muscle and bone tissue while attempting to avoid the broader hormonal effects associated with traditional anabolic steroids. Earlier research programs investigated enobosarm in conditions involving muscle wasting, including cancer-related cachexia and age-related muscle decline.

By pairing enobosarm with semaglutide, Veru Inc. is attempting to reposition the compound within the rapidly expanding obesity therapeutics market. The strategy assumes that incretin therapies will remain central to pharmacological weight loss because of their ability to regulate appetite and metabolic signaling. Complementary therapies may therefore address physiological consequences of weight reduction, particularly reductions in lean body mass.

The Phase 2b PLATEAU trial will enroll approximately 200 patients aged 65 years or older with obesity who are initiating semaglutide therapy. The primary efficacy endpoint is percentage change in total body weight at 68 weeks. Secondary endpoints include changes in fat mass, lean mass, bone mineral density, and measures of physical function such as stair-climbing performance and patient-reported physical capability.

Researchers will also evaluate metabolic indicators including hemoglobin A1c and insulin resistance markers, reflecting the close relationship between obesity and cardiometabolic disease. By incorporating these endpoints, the study aims to determine whether changes in body composition translate into broader metabolic benefits.

What the PLATEAU trial design reveals about evolving priorities in obesity clinical research

The structure of the PLATEAU trial highlights how obesity clinical research is expanding beyond traditional weight-based endpoints. Earlier obesity trials focused primarily on percentage weight reduction as the principal indicator of success. Increasingly, investigators are integrating body composition analysis and functional outcomes to better capture the physiological effects of treatment.

In this study, body composition will be measured using dual-energy X-ray absorptiometry scanning. This imaging technology allows precise differentiation between fat mass, lean tissue, and bone density, enabling researchers to determine how weight loss is distributed across different tissues. Such measurements are particularly important for evaluating therapies designed to preserve muscle during weight reduction.

Functional assessments also play a role in the study design. Measures such as stair-climb performance provide insight into muscle strength, endurance, and overall physical capability. Clinicians studying obesity therapies increasingly emphasize that functional outcomes may be more relevant to long-term health than weight change alone. The trial will also include an interim analysis at 34 weeks examining changes in lean body mass and fat mass before completion of the full study period. Interim results are expected in early 2027, while final topline data are anticipated later the same year.

Why combination pharmacology may become the next competitive phase in obesity therapeutics

The obesity therapeutics landscape is entering a phase in which pharmaceutical companies are exploring ways to differentiate treatments beyond appetite suppression alone. While incretin-based drugs have demonstrated remarkable efficacy, researchers increasingly believe that combination pharmacology may define the next stage of innovation in metabolic medicine.

Several approaches are currently under investigation. Some programs combine GLP-1 receptor agonists with glucagon receptor modulators designed to increase energy expenditure. Other strategies involve dual incretin pathways that influence appetite regulation and metabolic control simultaneously. Additional research explores hormones and peptides that affect satiety, nutrient partitioning, or metabolic efficiency.

The Veru Inc. strategy differs from many of these programs because it focuses on preserving lean mass rather than enhancing appetite suppression. If enobosarm successfully protects muscle during weight loss, the approach could introduce a new therapeutic dimension in obesity management. Instead of solely maximizing weight reduction, clinicians could aim for treatment strategies that improve metabolic health while maintaining functional muscle mass.

Industry observers suggest that such approaches could eventually support more personalized obesity treatment, where therapy selection reflects patient characteristics such as age, metabolic risk profile, and baseline muscle mass.

What unresolved safety and efficacy questions regulators may focus on as the PLATEAU trial advances

Despite the scientific rationale behind muscle-preserving obesity therapies, several uncertainties remain regarding how these approaches will be evaluated. Regulatory frameworks for obesity drugs historically focus on weight reduction thresholds and improvements in cardiometabolic markers. It remains uncertain how regulators will weigh endpoints related to lean mass preservation or physical function.

Safety considerations also remain central to the development of selective androgen receptor modulators. Although these compounds were designed to minimize systemic hormonal effects, regulators have previously scrutinized the class because of potential cardiovascular or hepatic risks. Demonstrating an acceptable safety profile will likely be critical if enobosarm progresses to late-stage clinical development.

Another question concerns whether improvements in body composition translate into meaningful clinical benefits. Preserving muscle mass during weight loss may appear advantageous, but researchers must demonstrate that such changes improve strength, mobility, metabolic stability, or long-term health outcomes.

Economic factors may also influence adoption. GLP-1 receptor agonists already represent some of the most expensive therapies in metabolic medicine. Combination pharmacology could further increase treatment costs unless clinical benefits justify the added complexity.

The PLATEAU trial therefore represents more than a single investigational program. It reflects a broader shift in obesity research toward understanding how pharmacological weight loss affects overall physiology. As the field evolves, clinicians and regulators may increasingly evaluate obesity therapies according to their ability to preserve functional health alongside reducing body weight.

  enobosarm, GLP-1 receptor agonists, obesity treatment, PLATEAU clinical trial, selective androgen receptor modulators, semaglutide, Veru Inc., Wegovy